Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer's Disease (CTAD) Conference TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. and B...
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension TOKYO, Nov 11, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessmen...
Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer's Disease TOKYO, Nov 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the Dominantly Inherit...
Eisai Presents New Data on the Relationship between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2b Study for Early Alzheimer's disease in Late-Breakers and Pipeline Updates at the Clinical Trials on Alzheimer's Disease (CTAD) Conference PR Newswire ...
Eisai and Digital Garage, Inc. Jointly Launch "Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)" TOKYO, Nov 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it launches the "Open Network Lab BioHealth Dementia Innovation Challenge (O...
Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study TOKYO, Nov 4, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of data from the company's extensive Alzheimer's disease (AD) pi...
Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 1, 2021 03:00 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - President, Neurology Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Fumiyoshi Sakai - Crédit Suisse ...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q2 earnings call. For further details see: Eisai Co., Ltd. 2022 Q2 - Results - Earnings Call Presentation
The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept) TOKYO, Nov 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) ...
Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...